Avantax Planning Partners, Inc. Avalo Therapeutics, Inc. Transaction History

Avantax Planning Partners, Inc.

  • $2.78 Billion
  • Q3 2024

Shares

1 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2022

Jul 18, 2022
BUY
$3.0 - $10.45 $37,971 - $132,265
12,657 New
12,657 $6,000

Others Institutions Holding AVTX

# of Institutions
1
Shares Held
34.6K
Call Options Held
0
Put Options Held
0
View Full List

About Avalo Therapeutics, Inc.

AVTX Quotes by TradingView
  • Ticker AVTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 9,414,100
  • Market Cap $91.6M
  • Description
  • Avalo Therapeutics, Inc., a clinical-stage precision medicine company, discovers, develops, and commercializes targeted therapeutics for patients with unmet clinical need in immunology, immuno-oncology, and rare genetic diseases. It develops AVTX-002, a fully human anti-LIGHT monoclonal antibody, which is under Phase II clinical trial for the tr...
More about AVTX
Track This Portfolio

Track Avantax Planning Partners, Inc. Portfolio

Follow Avantax Planning Partners, Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Avantax Planning Partners, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Avantax Planning Partners, Inc. with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email